Skip to main content
SpringerLink
Log in
Book cover

Regional Chemotherapy pp 57–85Cite as

Isolated Limb Perfusion for Malignant Melanoma and Soft Tissue Sarcoma

  • Chapter

  • 101 Accesses

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

In 1958, Creech et al. (1) introduced a novel method of drug delivery in advanced cancer, and named it isolated limb perfusion (ILP). The idea was to use the newly invented technique of cardiopulmonary bypass, which at that time had paved the way for open-heart surgery, in regional chemotherapy. They described a surgical method of exposing the major blood vessels of an extremity, providing its temporary isolation, and permitting perfusion of that extremity via the heart-lung machine, utilizing high doses of chemotherapeutic drugs. It would be possible to obtain high tissue concentrations of the drug with minimal systemic exposure and complications. Following the observation that heat on its own has antineoplastic properties (2), in 1969, Stehlin (3) modified the technique to include hyperthermia. Since then, ILP with melphalan, more than any other drug, has been widely recognized as the standard treatment strategy for advanced extremity melanoma.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Creech O, Krementz ET, Ryan RF, et al. Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit, Ann. Surg., 148 (1958) 616–631.

    PubMed  Google Scholar 

  2. Cavaliere R, Ciocatto EC, Giovanella BC, et al. Selective heat sensitivity of cancer cells: biochemical and clinical studies, Cancer, 20 (1967) 1351–1381.

    PubMed  CAS  Google Scholar 

  3. Stehlin JS. Hyperthermic perfusion with chemotherapy for cancers of the extremities, Surg. Gyncol. Obstet., 129 (1969) 305–308.

    Google Scholar 

  4. Lienard D, Ewalenko P, Delmotti JJ, et al. High dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J. Clin. Oncol., 10 (1992) 52–60.

    PubMed  CAS  Google Scholar 

  5. Muchmore JH, Krementz ET, and Kerstein MD. Noninvasive evaluation of peripheral vasculature following regional hyperthermic chemotherapeutic perfusion (RHCP), Am. Surg., 53 (1987) 94–96.

    PubMed  CAS  Google Scholar 

  6. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions, Eur. Cancer Clin. Oncol., 18 (1982) 905–910.

    CAS  Google Scholar 

  7. Sorkin P, Abu-Abid S, Lev D, et al. Systemic leakage and side effects of tumor necrosis factor administered via isolated limb perfusion can be manipualted by flow rate adjustment, Arch. Surg., 130 (1995) 1079–1084.

    PubMed  CAS  Google Scholar 

  8. Barker WC, Andrich MP, Alexander HR, et al. Continuous intraoperative external monitoring of perfusate leak using I-131 human serum albumin during isolated perfusion of the liver and limbs, Eur. J. Nucl. Med., 22 (1995) 1242–1248.

    PubMed  CAS  Google Scholar 

  9. Thom AK, Alexander HR, Andrich MP, et al. Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion (ILP) with high-dose TNF, interferon-gamma and melphalan, J. Clin. Oncol., 13 (1995) 264–273.

    PubMed  CAS  Google Scholar 

  10. Eggermont AMM, Schraffordt-Koops H, Klausner JM, et al. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas: the cumulative multicenter European experience, Ann. Surg., 224 (1996) 756–765.

    PubMed  CAS  Google Scholar 

  11. Minor DR, Allen RE, Alberts D, et al. Clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma, Cancer, 55 (1985) 2638–2644.

    PubMed  CAS  Google Scholar 

  12. Stehlin JS. Hyperthermic perfusion for melanoma of the extremeties: experience with 165 patients 1976 to 1979, Ann. NY Acad. Sci., 335 (1980) 352–355.

    PubMed  Google Scholar 

  13. Benckhuijsen C, Kroon BBR, Van Geel AN, et al. Regional perfusion treatment with melphalan for melanoma in a limb. An evaluation of drug kinetics, Eur. J. Surg. Oncol., 14 (1988) 157–163.

    PubMed  CAS  Google Scholar 

  14. Scott RN, Kerr KJ, Mackie R, et al. Pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma, Br. J. Cancer, 68 (1992) 159–166.

    Google Scholar 

  15. Briele HA, Dyuric M, Jung DT, et al. Pharmacokinetics of melphalan in clinical isolation perfusion of the extremities, Cancer Res., 45 (1985) 1885–1889.

    PubMed  CAS  Google Scholar 

  16. Ghussen F, Kruger I, Groth W, et al. Role of hyperthermic cytostatic perfusion in the treatment of extremity melanoma, Cancer, 61 (1988) 654–659.

    PubMed  CAS  Google Scholar 

  17. Hafstrom L, Rudenstam CM, Blomquist E, et al. Regional hyperthermic perfusion with melphalan after surgery for recurrent melanoma of the extremities, J. Clin. Oncol., 9 (1991) 2091–2094.

    PubMed  CAS  Google Scholar 

  18. Lienard D, Eggermont AM, Kroon BBR, et al. Isolated limb perfusion in primary and recurrent melanoma: indications and results, Semin. Surg. Oncol., 14 (1998) 202–209.

    PubMed  CAS  Google Scholar 

  19. Balch CM, Soong SJ, Shin HM, et al. Changing trends in the clinical and pathologic features of melanoma, In Balch CM, et al. (eds), Cutaneous Melanoma. Lippincott, Philadelphia, (1992) pp. 40–45.

    Google Scholar 

  20. Klein ES and Ben-Ari GY. Isolation perfusion with cisplatin for malignant melanoma of the limbs, Cancer, 59 (1987) 1068–1071.

    PubMed  CAS  Google Scholar 

  21. Guchelaar JH, Hoekstra HJ, de Vries EG, et al. Cisplatin and platinum pharmacokinetics during hyperthermic isolated limb perfusion for human tumors of the extremities, Br. J. Cancer, 65 (1992) 898–902.

    PubMed  CAS  Google Scholar 

  22. Fletcher WS, Pommier R, and Small K Results of cisplatin hyperthermic isolation perfusion for stage IIIA and IIIAB extremity melanoma, Melanoma Res., 4 (1994) 17–19.

    PubMed  Google Scholar 

  23. Roseman JM. Effective management of extremity cancers using cisplatin and etoposide in isolated limb perfusions, J. Surg. Oncol., 35 (1987) 170–172.

    PubMed  CAS  Google Scholar 

  24. Martijn H, Oldhoff J, and Koops HS. Hyperthermic regional perfusion with melphalan and a combination of melphalan and actinomycin D in the treatment of locally metastasized malignant melanomas of the extremities, J. Surg. Oncol., 20 (1982) 9–13.

    PubMed  CAS  Google Scholar 

  25. Didolkar MS, Fitzpatrick JL, Jackson AJ, et al. Toxicity and complications of vascular isolation and hyperthermic perfusion with imidazole carboxamide (DITC) in melanoma, Cancer, 57 (1986) 1961–1966.

    PubMed  CAS  Google Scholar 

  26. Klaase JM, Kroon BBR, Benckhuysen C, et al. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities, Cancer, 64 (1989) 616–621.

    PubMed  CAS  Google Scholar 

  27. Rossi CR, Vecchiato A, Foletto M, et al. Phase II study on neoadjuvant hyperthermic-antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas, Cancer, 73 (1994) 2140–2146.

    PubMed  CAS  Google Scholar 

  28. Carswell EA, Old LJ, Kassel RL, et al. Endotoxin-induced serum factor that causes necrosis of tumors, Proc. Natl. Acad. Sci. USA, 72 (1975) 3666–3670.

    PubMed  CAS  Google Scholar 

  29. Aggarwal BB, Kohr WJ, Hass PE, et al. Human tumor necrosis factor: production, purification and characterization, J. Biol. Chem., 260 (1985) 2345–2354.

    PubMed  CAS  Google Scholar 

  30. Haranaka K, Satomi N, and Sukari A. Antitumor activity of murine tumor necrosis factor against transplanted murine tumors and heterotransplanted human tumors in nude mice, Int. J. Cancer, 34 (1984) 263–267.

    PubMed  CAS  Google Scholar 

  31. Asher AL, Mule JY, Reichert CM, Shiloni E, and Rosenberg SA. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo, J. Immunol., 138 (1987) 963–974.

    PubMed  CAS  Google Scholar 

  32. Spriggs DR, Sherman ML, Michie H, et al. Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study, J. Natl. Cancer Inst., (1988) 1039–1044.

    Google Scholar 

  33. Chapman PB, Lester Ti, Casper ES, et al. Clinical pharmacoogy of recombinant human tumor necrosis factor in patients with advanced cancer, J. Clin. Oncol., 5 (1987) 1942–1951.

    PubMed  CAS  Google Scholar 

  34. Feinberg B, Kurzrock R, Talpaz M, et al. Phase I trial of intravenously administered recombinant tumor necrosis factor alpha in cancer patients, J. Clin. Oncol., 6 (1988) 1328–1334.

    PubMed  CAS  Google Scholar 

  35. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin, Science, 234 (1986) 470–473.

    PubMed  CAS  Google Scholar 

  36. Beutler B and Cerami A. Tumor necrosis, cachexia shock and inflammation; a common mediator, Ann. Rev. Biochem., 57 (1988) 505–518.

    PubMed  CAS  Google Scholar 

  37. Bevilcqua MP, Pober JS, Majeau GR, et al. Recombinant tumor necrosis factor induces coagulant activity in cultured human vasculature endothelium; characterization and comparison with actions of interleukin-1, Proc. Natl. Acad. Sci. USA, 83 (1986) 4533–5437.

    Google Scholar 

  38. Lejeune FJ. High-dose recombinant tumour necrosis factor (rTNFa) administered by isolation perfusion for advanced tumours of the limbs: a model for biochemotherapy of cancer, Eur. J. Cancer, 81 (1995) 1009–1016.

    Google Scholar 

  39. Alexander HR, Fraker DL, and Bartlett DL. Isolated limb perfusion for malignant melanoma, Semin. Surg. Oncol., 12 (1996) 416–426.

    PubMed  Google Scholar 

  40. Hill S, Fawcett WJ, Sheldon J, et al. Low-dose tumour necrosis factor alpha and melphalan in hyperthermic isolated limb perfusion, Br. J. Surg., 80 (1993) 995–997.

    PubMed  CAS  Google Scholar 

  41. Spriggs DR, Sherman ML, Frei E III, et al. Clinical studies with tumor necrosis factor, In Old LJ (ed), Ciba Foundation Symposium 131, Tumor Necrosis Factor and Related Cytotoxins. Wiley, New York, (1987) 206–227.

    Google Scholar 

  42. Sugarman BJ, Aggarwal BB, Hass PF, et al. Recombinant tumor necrosis factor-a: effects of proliferation of normal and transformed cells in vitro, Science, 230 (1985) 943–945.

    PubMed  CAS  Google Scholar 

  43. Quinn TD, Polk HC Jr, and Edwards J. Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines, Cancer Immunol. Immunother., 40 (1995) 272–275.

    PubMed  CAS  Google Scholar 

  44. Renard N, Lienard D, Gaspanard L, et al. Early endothelian activation and polymorphonuclear cell invasion precede specific necrosis of human melanoma and sarcoma treated by intravascular high-dose tumor necrosis factor alpha (TNF-a), Int. J. Cancer, 57 (1994) 656–663.

    PubMed  CAS  Google Scholar 

  45. Manusoma ER, Stavast J, Marquet RC, et al. Total body irradiaiton (TBI) attenuates antitumor effects of TNFa in isolated limb perfusion (ILP) in the rat, Eur. J. Surg. Res., 27 (1995) 110

    Google Scholar 

  46. Watanabe N, Niitsu Y, Umeno H, et al. Toxic effect of TNF on tumor vasculature in mice, Cancer Res., 49 (1988) 2179–2183.

    Google Scholar 

  47. Nawroth PP and Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor, J. Exp. Med., 163 (1986) 740–745.

    PubMed  CAS  Google Scholar 

  48. Cheresh DA. Death to a blood vessel, death to a tumor, Nature Med., 4 (1998) 395–396.

    PubMed  CAS  Google Scholar 

  49. Ruegg C. Evidence for the involvement of endothelial cell integrin aV133 in the disruption of the tumor vasculature induced by TNF and IFN-y, Nature Med., 4 (1998) 408–414.

    PubMed  CAS  Google Scholar 

  50. Regeness A, Muller M, Curschellas E, et al. Antitumor effects of tumor necrosis factor in combination with chemotherapeutic agents, Int. J. Cancer, 39 (1987) 266–273.

    Google Scholar 

  51. Folli S, Pelegrin A, Chalandon Y, et al. Tumor necrosis factor can enhance radio-antibody uptake in human colon carcinoma xenografts by increasing vascular permeability, Int. J. Cancer, 53 (1993) 829–836.

    PubMed  CAS  Google Scholar 

  52. Brown CK, Bartlett SK, Libuth E, et al. Augmental capillary leak during isolated hepatic perfusion (IHP) occurs via ILP independent mechanisms (abstract). 51st Annual Cancer Symposium, SSO, San Diego, 26–29 March 1998, 24, 12.

    Google Scholar 

  53. Krosnick JA, Mule JJ, Mclntosj JK, et al. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo, Cancer Res., 49 (1989) 3729–3733.

    PubMed  CAS  Google Scholar 

  54. Watanabe N, Niitso Y, Umeno N, et al. Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia, Cancer Res., 48 (1988) 650–653.

    PubMed  CAS  Google Scholar 

  55. Aggarwell BB, Eessalu TE, and Hass PE. Characterization of receptors for tumor necrosis factor and their regulation by gamma-interferon, Nature, 318 (1985) 665–667.

    Google Scholar 

  56. Balkwill FR, Lee A, Aldam G, et al. Human tumor xenografts treated with recombinant human necrosis factor alone or in combination with interferons, Cancer Res., 46 (1986) 3990–3993.

    PubMed  CAS  Google Scholar 

  57. Eggermont AMM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-a in combination with interferon-y and melphalan for non-resectable extremity soft tissue sarcoma: a multicenter trial, J. Clin. Oncol., 14 (1996) 2653–2665.

    PubMed  CAS  Google Scholar 

  58. Belli F, Arienti F, Rivoltini L, et al. Treatment of recurrent in-transit metastases from cutaneous melanoma by isolation perfusion in extracorporeal circulation with interleukin-2 and lymphokine activated killer cells. A pilot study. Melanoma Res., 2 (1992) 263–271.

    PubMed  CAS  Google Scholar 

  59. Lejeune FJ, Deloof T, Ewalenko P, et al. Objective regression of unexcised melanoma in-transit metastases after hyperthermic isolation perfusion of the limbs with melphalan. Recent results, Cancer Res., 86 (1983) 268–276.

    CAS  Google Scholar 

  60. Dickson JA and Calderwood SK. Temperature range and selective sensitivity of tumors to hyperthermia. A critical review, Ann. NY Acad. Sci., 335 (1980) 180–201.

    PubMed  CAS  Google Scholar 

  61. Dietzel F. Basic principles in hyperthermic tumor therapy. Recent results, Cancer Res., 86 (1983) 177–190.

    CAS  Google Scholar 

  62. Robbins HI, d’Oleire F, Kutz M, et al. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8°C hyperthermia, Cancer Lett., 89 (1995) 55–62.

    Google Scholar 

  63. Vrouenraets BC, Klaase JM, Nieweg 0E, et al. Toxicity and morbidity of isolated limb perfusion, Semin. Surg. Oncol., 14 (1998) 224–231.

    PubMed  CAS  Google Scholar 

  64. Baas PC, Schraffordt Koops H, Hoekstra HJ, et al. Groin dissection in the treatment of lower-extremity melanoma: short-and long-term morbidity, Arch. Surg., 127 (1992) 281–286.

    PubMed  CAS  Google Scholar 

  65. Klaase JM, Kroon BB, van Geel AN, et al. Patient and treatment related factors associated with acute regional toxicity after isolated perfusion for melanoma of the extremities, Am. J. Surg., 167 (1994) 618–620.

    PubMed  CAS  Google Scholar 

  66. Vrouenraets BC, Klaase JM, Kroon BB, et al. Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions, Arch. Surg., 130 (1995) 43–47.

    PubMed  CAS  Google Scholar 

  67. Klaase JM, Kroon BB, van Slooten GW, et al. Relation between calculated melphalan peak concentrations and toxicity in regional isolated perfusion for melanoma, Reg. Cancer Treat., 4 (1992) 309–312.

    Google Scholar 

  68. Thompson JF, Eksborg S, Kam PC, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma, Melanoma Res., 6 (1996) 267–271.

    PubMed  CAS  Google Scholar 

  69. Gutman M, Inbar M, Shlush-Lev D, et al. High-dose tumor necrosis factor alpha and melphalan administered via isolated limb perfusion for advanced soft tissue sarcoma results in a >90% response rate and limb preservation, Cancer, 79 (1997) 1129–1137.

    PubMed  CAS  Google Scholar 

  70. Fraker DL and Alexander HR. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma, Important Adv. Oncol., 1994 (1994) 179–192.

    Google Scholar 

  71. Yang JC, Fraker DL, Thom AK, et al. Isolation perfusion with tumor necrosis factor-a, interferon-’y, and hyperthermia in the treatment of localized and metastatic cancer, Recent Res. Cancer Res., 138 (1995) 161–166.

    CAS  Google Scholar 

  72. Kroon BB, Klaase JM, van Geel BN, et al. Application of hyperthermia in regional isolated perfusion for melanoma of the limbs, Reg. Cancer Treat., 4 (1992) 223–226.

    Google Scholar 

  73. Lai DT, Ingvar C, and Thompson JF. Value of monitoring serum creatine phosphokinase following hyperthermic isolated limb perfusion for melanoma, Reg. Cancer Treat., 1 (1993) 36–39.

    Google Scholar 

  74. Klaase JM, Kroon BB, van Geel AN, et al. Retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb, Cancer, 71 (1993) 2990–2994.

    PubMed  CAS  Google Scholar 

  75. Vrouenraets BC, Eggermont AM, Klaase JM, et al. Long-term neuropathy after regional isolated perfusion with melphalan for melanoma of the limbs, Eur. J. Surg. Oncol., 20 (1994) 681–685.

    PubMed  CAS  Google Scholar 

  76. Rosin DR. Isolated limb perfusion: past experience and present studies using a minimal-access approach, Melanoma Res., 4 (suppl 1) (1994) 51–55.

    PubMed  Google Scholar 

  77. Hoekstra HJ, Naujocks T, Schraffordt Koops H, et al. Continuous leakage monitoring during hyper-thermic isolated regional perfusion of the lower limb: techniques and results, Reg. Cancer Treat., 4 (1992) 301–304.

    Google Scholar 

  78. Thompson JF, Kam PC, Razan D, et al. Clinical pharmacokinetics of melphalan in isolated limb perfusion; compartmental modelling and moment analysis, Reg. Cancer Treat., 8 (1994) 83–87.

    Google Scholar 

  79. Gerain J, Lienard D, Ewalenko P, et al. High serum levels of TNFa after its administration for isolation perfusion of the limbs, Cytokine, 4 (1992) 585–591.

    PubMed  CAS  Google Scholar 

  80. Salomon GD, Kasid A, Cromack DT, et al. Local effects of cachectin/tumor necrosis factor in wound healing, Ann. Surg., 214 (1991) 175–180.

    PubMed  CAS  Google Scholar 

  81. McBride CM, Sugarbaker EV, and Hickey RC. Prophylactic isolation-perfusion as the primary therapy for invasive malignant melanoma of the limbs, Ann. Surg., 192 (1975) 316–324.

    Google Scholar 

  82. Golomb FM, Bromberg J, and Dubin N. Controlled study of the survival experience with primary malignant melanoma of the distal extremities treated with adjuvant isolated perfusion, In Jones SE and Solomon SE (eds), Adjuvant Therapy of Cancer II. Grune & Stratton, New York, 1979, pp. 519–526.

    Google Scholar 

  83. Rege VB, Leone LA, Soderberg CH, et al. Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review, Cancer, 52 (1983) 2033–2039.

    PubMed  CAS  Google Scholar 

  84. Fletcher JR, White CR, and Retch WS. Improved survival rates of patients with acral lentiginous melanoma treated with hyperthermic isolation perfusion, wide excision and regional lymphadenopathy, Am. J. Surg., 151 (1986) 593–598.

    PubMed  CAS  Google Scholar 

  85. Martijn H, Koops HS, Milton GW, et al. Comparison of two methods of treating primary melanomas Clark IV and V, thickness 1.5mm and greater localized on the extremities-wide surgical excision with and without adjuvant regional perfusion, Cancer, 57 (1986) 1923–1930.

    PubMed  CAS  Google Scholar 

  86. Franklin H, Koops HS, Oldhoff J, et al. To perfuse or not to perfuse? A retrospective comparative study to evaluate the effect of adjuvant isolated regional perfusion in patients with stage I extremity melanoma with a thickness of 1.5mm or greater, J. Clin. Oncol., 6 (1988) 701–708.

    PubMed  CAS  Google Scholar 

  87. Edwards MJ, Soong SJ, Boddie AW, et al. Isolated limb perfusion for localized melanoma of the extremity, Arch. Surg., 125 (1990) 317–321.

    PubMed  CAS  Google Scholar 

  88. Vrouenraets BC, Kroon BBR, Klaase JM, et al. Adjuvant regional isolated perfusion with melphalan for patients with Clark C melanoma of the extremities, J. Surg. Oncol., 52 (1993) 249–254.

    PubMed  CAS  Google Scholar 

  89. Schraffordt-Koops H, Kroon BBR, Oldhoff J, et al. Controversies concerning adjuvant isolated perfusion for stage I melanoma of the extremities, World J. Surg., 16 (1992) 241–245.

    PubMed  CAS  Google Scholar 

  90. Ghussen F, Kruger I, Smalley RV, et al. Hyperthermic perfusion with chemotherapy for melanoma of the extremities, World J. Surg. 13 (1989) 598–602.

    PubMed  CAS  Google Scholar 

  91. Turnbull A, Shah J, and Fortner J. Recurrent melanoma of an extremity treated by major amputation, Arch. Surg., 106 (1973) 496–498.

    PubMed  CAS  Google Scholar 

  92. Jaques DP, Coit DG, and Brenman MF. Major amputation for advanced malignant melanoma, Surg. Gynecol. Obstet., 169 (1989) 1–6.

    PubMed  CAS  Google Scholar 

  93. Hafstrom L and Jonsson PE. Hyperthermic perfusion of recurrent malignant melanoma of the extremities, Acta. Chir. Scand., 146 (1980) 313–318.

    PubMed  CAS  Google Scholar 

  94. Bulman AS and Jamieson CW. Isolated limb perfusion with melphalan in the treatment of melanoma, Br. J. Surg., 67 (1980) 660–662.

    PubMed  CAS  Google Scholar 

  95. Kroon BB, van Geel AN, Benckhuijsen C, et al. Normothermic isolation perfusion with melphalan for advanced melanoma of the limbs, Anticancer Res., 7 (1987) 441–442.

    PubMed  CAS  Google Scholar 

  96. Skene AI, Bulman AS, Williams TR, et al. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma of the lower limb, Br. J. Surg., 77 (1990) 765–767.

    PubMed  CAS  Google Scholar 

  97. Klaase JM, Kroon BB, van Geel AN, et al. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion using melphalan, Surgery 115 (1994) 39–45.

    PubMed  CAS  Google Scholar 

  98. Bryant PJ, Balderson GA, Mead P, et al. Hyperthermic isolated limb perfusion for malignant melanoma: response and survival, World J. Surg., 19 (1995) 363–368.

    PubMed  CAS  Google Scholar 

  99. Lejeune FJ, Lienard D, el Douaihy M, et al. Results of 206 isolated limb perfusions for malignant melanoma, Eur. J. Surg. Oncol., 15 (1989) 510–519.

    PubMed  CAS  Google Scholar 

  100. Klaase JM, Kroon BB, van Geel AN, et al. Limb recurrence-free interval and survival in patients with recurrent melanoma of the extremities treated with normothermic isolated perfusion, J. Am. Coll. Surg., 178 (1994) 564–572.

    PubMed  CAS  Google Scholar 

  101. Oldhoff HM and Koops HS. Regional perfusion in the treatment of patients with locally metastasized, malignant melanoma of the limbs, Eur. J. Cancer, 17 (1981) 471–476.

    PubMed  Google Scholar 

  102. Krementz ET, Sutherland CM, and Muchmore JH. Isolated hyperthermia chemotherapy perfusion for limb melanoma, Surg. Clin. N. Am., 76 (1996) 1313–1331.

    PubMed  CAS  Google Scholar 

  103. Hoekstra HJ, Koops HS, de Vries LG, et al. Toxicity of hyperthermic isolated limb perfusion with cisplatin for recurrent melanoma of the lower extremity after previous perfusion, Cancer, 72 (1993) 1224–1229.

    PubMed  CAS  Google Scholar 

  104. Didolkar MS, Viens ML, Suter CM, et al. Phase II study of isolation perfusion with DITC in stage IIIa-Illab melanoma of the extremity, Proc. Am. Soc. Clin. Oncol., 9 (1990) 276.

    Google Scholar 

  105. Cavaliere R, Cavaliere F, Deeraco M, et al. Hyperthermic antiblastic perfusion in the treatment of stage IIIA-IIIB melanoma patients. Comparison of two experiences, Melanoma Res., 4 (1994) 5–11.

    PubMed  Google Scholar 

  106. Shiu MH, Knapper WH, Fortner JG, et al. Regional isolated limb perfusion of melanoma in-transit metastases using mechlorethamine (nitrogen mustard), J. Clin. Oncol., 4 (1986) 1819–1826.

    PubMed  CAS  Google Scholar 

  107. Fraker DL, Alexander HR, Andrich MP, et al. Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon-gamma: results of a tumor necrosis factor dose-escalation study, J. Clin. Oncol., 14 (1996) 479–489.

    PubMed  CAS  Google Scholar 

  108. Gutman M, Lev-Chelouche D, Abu-Abeid S, Inbar M, and Klausner JM. Isolated limb perfusion with tumor necrosis factor and melphalan for locally advanced malignant melanoma. Ninth Congress of the European Society of Surgical Oncology, Lausanne, Switzerland, 3–6 June 1998.

    Google Scholar 

  109. Hohenberger P and Kettelhack C. Clinical management and current research in isolated limb perfusion for sarcoma and melanoma, Oncology, 55 (1998) 89–102.

    PubMed  CAS  Google Scholar 

  110. Fraker DL, Alexander HR, Bartlett DL, et al. Prospective randomized trial of therapeutic isolated limb perfusion (ILP) comparing melphalan (M) versus melphalan, tumor necrosis factor (TNF) and interferon-gamma (IFN): an initial report, Soc. Surg. Oncol., 49 (1996) 6

    Google Scholar 

  111. Barlett DL, Ma G, Alexander HR, et al. Isolated limb reperfusion with tumor necrosis factor and melphalan in patients with extremity melanoma after failure of isolated limb perfusion with chemotherapeutics, Cancer, 80 (1997) 2084–2090.

    Google Scholar 

  112. Gaynor JJ, Tan CC, Casper ES, et al. Refinement of clinicopathologic staging for localized soft tissue sarcoma of the extremity: a study of 423 adults, J. Clin. Oncol., 10 (1992) 1317–1327.

    PubMed  CAS  Google Scholar 

  113. Lawrence W, Donegan WL, Natrajan N, et al. Adult soft tissue sarcomas: a pattern of care survey of the American College of Surgeons, Ann. Surg., 205 (1987) 349–359.

    PubMed  Google Scholar 

  114. Eilber FR, Eckhardt JF, Rosn G, et al. Neoadjuvant chemotherapy and radiotherapy in the multidisciplinary management of soft tissue sarcomas of the extremity, Surg. Oncol. Clin. North. Am., 2 (1993) 611–620.

    Google Scholar 

  115. Hoekstra HJ, Mehta DN, Wigffels RT, et al. Local tumor control by intraoperative radiotherapy (IORT): a pilot experience, Eur. J. Surg. Oncol., 17 (1996) 364–369.

    Google Scholar 

  116. Krementz ET, Carter RD, Sutherland CM, et al. Chemotherapy of sarcomas of the limbs by regional perfusion, Ann. Surg., 185 (1977) 555–564.

    PubMed  CAS  Google Scholar 

  117. Pommier RF, Moseley HS, Cohen J, et al. Pharmacokinetics, toxicity and short-term results of cisplatin hyperthermic isolated limb perfusion for soft tissue sarcoma and melanoma of the extremities, Am. J. Surg., 155 (1988) 667–671.

    PubMed  CAS  Google Scholar 

  118. Sijens PE, Eggermont AMM, van Dijk P, et al. 31P magnetic resonance spectroscopy as predictor for clinical response in human extremity sarcoma treated by single dose TNF-alpha and melphalan isolated limb perfusion, NMR Biomed., 8 (1995) 215–221.

    PubMed  CAS  Google Scholar 

  119. Nieweg OF, Pruim J, Hoekstra HY, et al. Positron emission tomography with fluorine-18-fluorodeoxyglucose for the evaluation of therapeutic isolated regional limb perfusion in a patient with soft tissue sarcoma, J. Nucl. Med., 35 (1994) 90–92.

    PubMed  CAS  Google Scholar 

  120. Schraffordt-Koops H, Lienard N, Eggermont AMM, et al. Isolated limb perfusion with high-dose ENF-alpha, gamma-IFN, and melphalan in patients with irresectable soft tissue sarcomas; a highly effective limb saving surgery. 46th Annual Cancer Symposium, Society of Surgical Oncology, Los Angeles, 18–21 March 1998, 4 1 (Abstract).

    Google Scholar 

  121. Vaglini M, Belli F, Ammatuna M, et al. Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor gamma interferon and melphalan, Cancer, 73 (1994) 483–492.

    PubMed  CAS  Google Scholar 

  122. Lev D, Abu-Abid S, Issakov J, et al. Isolated limb perfusion (ILP) with tumor necrosis factor (TNF) and melphalan for multifocal soft tissue sarcoma (STS): Limb salvage in fatal disease. 51st Annual Cancer Symposium WFSOS (World Federation of Societies of Surgical Oncology), San Diego, 26–29 March 1998, W47, p. 42 (Abstract).

    Google Scholar 

Download references

Authors
  1. Joseph M. Klausner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dina Lev-Chelouche
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Subhi Abu-Abeid
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mordechai Gutman
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Maurie Markman MD (Director, Chairman) (Director, Chairman)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Klausner, J.M., Lev-Chelouche, D., Abu-Abeid, S., Gutman, M. (2000). Isolated Limb Perfusion for Malignant Melanoma and Soft Tissue Sarcoma. In: Markman, M. (eds) Regional Chemotherapy. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-219-7_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-219-7_5

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9697-0

  • Online ISBN: 978-1-59259-219-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation